Starpharma Holdings Limited
Starpharma Holdings Limited
Your view on SPHRF
Overview
What the company does, where it operates, and who runs it.
About Starpharma Holdings Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cheryl Maley
- Headquarters
- 4-6 Southampton Crescent, Abbotsford, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cheryl Maley
- Headquarters
- 4-6 Southampton Crescent, Abbotsford, VIC, AU
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis.
The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray.
In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies.
The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Starpharma Holdings Limited, and the rating behind it. SPHRF last traded at $0.32; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Starpharma Holdings Limited. Starting points for Starpharma Holdings Limited: EPS -$0.02, beta 0.49 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Starpharma Holdings Limited. Starpharma Holdings Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Starpharma Holdings Limited. Trailing twelve-month EPS for Starpharma Holdings Limited stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Starpharma Holdings Limited. Starpharma Holdings Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Starpharma Holdings Limited valued side by side against its closest peers. Starpharma Holdings Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Starpharma Holdings Limited, and how their positions are changing. At a $134.4M market value, institutional positions materially move Starpharma Holdings Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Starpharma Holdings Limited executives and directors. Shares of Starpharma Holdings Limited have traded between $0.06 and $0.39 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Starpharma Holdings Limited. Starpharma Holdings Limited is a $134.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Starpharma Holdings Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Starpharma Holdings Limited. Coverage tracks Starpharma Holdings Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.